Last reviewed · How we verify
Ondansetron, dexamethasone, aprepitant
This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different molecular pathways.
This is a fixed-dose combination of three antiemetic agents that work synergistically to prevent chemotherapy-induced nausea and vomiting (CINV) through different molecular pathways. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.
At a glance
| Generic name | Ondansetron, dexamethasone, aprepitant |
|---|---|
| Also known as | Aprepitant = Emend, ARM A |
| Sponsor | University of Oklahoma |
| Drug class | Antiemetic combination (5-HT3 antagonist, NK1 antagonist, corticosteroid) |
| Target | 5-HT3 receptor, NK1 receptor, glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ondansetron is a 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone. Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the central nervous system. Dexamethasone is a corticosteroid that provides additional antiemetic effects through multiple mechanisms. Together, these agents target complementary pathways to provide comprehensive CINV prevention.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
Common side effects
- Headache
- Constipation
- Diarrhea
- Fatigue
- Insomnia
Key clinical trials
- Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile (PHASE2)
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients (PHASE3)
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data (PHASE3)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer (PHASE3)
- Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery. (PHASE4)
- Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |